AzTrials
AzTrials

Cow's Milk Protein Allergy Protein Intolerance Failure to ThriveNCT07174999

Nutritional Evaluation of Infants Receiving Amino Acid-Based Formula

An observational study of Cow's Milk Protein Allergy Protein Intolerance Failure to Thrive, run by Assiut University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to evaluate the growth parameters and nutritional status of infants who are receiving amino acid-based formula due to cow's milk protein allergy or other medical indications. Read more about this study

Who is it for?
Ages 1 month to 12 months
How many people
160 participants
Where
1 siteEgypt
Study dates
1 Jan 2026to 30 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 12 months
  • All sexes
  • No healthy volunteers
  • Child

Study population: The study population will include infants aged 1 to 12 months who are exclusively or predominantly receiving amino acid-based formula (AAF) as part of their routine medical care due to established clinical indications.

Who may be able to join

  • Infants aged 1 to 12 months at the time of enrollment.
  • Infants who are exclusevel or predominantly fed amino acid-based formula (AAF) in addition to elimination diet for at least 12 consecutive weeks.
  • Infants who are diagnosed as CMPA by CoMiSS score ≥ 10 and confirmed by OFC test.
  • Infants with informed parental or guardian consent to participate in the study.

Who cannot join

  • 1- Infants with congenital anomalies or syndromes affecting growth and development (e.g., trisomy 21, major cardiac defects).
  • 2- Infants with chronic systemic illnesses unrelated to feeding (e.g., cystic fibrosis, chronic kidney disease).
  • 3- Infants receiving additional specialized nutrition support (e.g., parenteral nutrition or tube feeding not involving AAF).
  • 4- Infants with incomplete or insufficient medical records at the time of assessment.5- Infants who have been on AAF for less than 4 weeks or whose feeding regimen is not stable.
  • 6- Infants whose parents or legal guardians decline or withdraw informed consent.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Merna Emeel Fahmy, MBBCh, Pediatric Resident contact

01202626579

Merna.17289584@med.aun.edu.eg

Osama Mahmoud Elasheer, prof contact

01001348864

asheer1970@aun.edu.eg

Egypt1 site
  • Assiut University

    Asyut

Other trials in Egypt

About this study

Official title: Prospective Observational Study for Nutritional Evaluation of Infants Receiving Amino Acid-Based Formula at Assiut University Children's Hospital

This study aims to evaluate the growth parameters and nutritional status of infants who are receiving amino acid-based formula due to cow's milk protein allergy or other medical indications.

Read the detailed description

This prospective observational study will assess infants who are exclusively fed amino acid-based formula. Participants will be followed over a period of 6 months, and anthropometric measurements (weight, length, head circumference) will be recorded monthly. Growth velocity and nutritional status will be analyzed and compared with WHO growth standards.

Keywords
Amino Acid-Based Formula Infant Nutrition Growth Assessment Food Allergy Nutritional Evaluation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07174999
Study groupRoleWhat they receive
Study PopulationInfants receiving amino acid-based formula who are evaluated at the Nutrition and Gastroenterology Departments, Assiut University Children's Hospital.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean anthropometric z-scores (WAZ, LAZ, WLZ)

    Mean weight-for-age, length-for-age, and weight-for-length z-scores for the study population compared to WHO reference.

    Measured: Single assessment at enrollment.

  2. Weight-for-Age Z-score (WAZ) - prevalence of underweight

    Prevalence of underweight (weight-for-age z-score < -2) among infants receiving amino acid-based formula, calculated according to WHO growth standards.

    Measured: Single assessment at enrollment.

  3. Nutritional Status (Weight-for-Age Z-sco

    Assessment of weight-for-age z-score in infants receiving amino acid-based formula compared to WHO growth standards.

    Measured: At the time of enrollment (single assessment).

Secondary outcomes (3)
  1. Length-for-Age Z-score

    Measurement of length-for-age z-score according to WHO growth standards.

    Measured: At the time of enrollment.

  2. Head Circumference-for-Age Z-score

    Measurement of head circumference-for-age z-score according to WHO growth standards.

    Measured: At the time of enrollment.

  3. Gastrointestinal Symptoms

    Assessment of gastrointestinal tolerance including vomiting, diarrhea, and constipation

    Measured: At the time of enrollment (parental report).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2025
  2. Study start1 Jan 2026 (estimated)
  3. Primary completion30 Dec 2026 (estimated)
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
160 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07174999
Sponsor's protocol ID
AA-Formula-Study-2025
Status last verified
Sep 2025
First submitted
9 Sep 2025
Last updated
16 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Fiocchi A, Brozek J, Schunemann H, Bahna SL, von Berg A, Beyer K, Bozzola M, Bradsher J, Compalati E, Ebisawa M, Guzman MA, Li H, Heine RG, Keith P, Lack G, Landi M, Martelli A, Rance F, Sampson H, Stein A, Terracciano L, Vieths S. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. World Allergy Organ J. 2010 Apr;3(4):57-161. doi: 10.1097/WOX.0b013e3181defeb9. Epub 2010 Apr 23. No abstract available.

    PubMed 23268426
  • Koletzko S, Niggemann B, Arato A, Dias JA, Heuschkel R, Husby S, Mearin ML, Papadopoulou A, Ruemmele FM, Staiano A, Schappi MG, Vandenplas Y; European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI Committee practical guidelines. J Pediatr Gastroenterol Nutr. 2012 Aug;55(2):221-9. doi: 10.1097/MPG.0b013e31825c9482.

    PubMed 22569527

Questions about this trial

What is this clinical trial studying?

An observational study of Cow's Milk Protein Allergy Protein Intolerance Failure to Thrive, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Merna Emeel Fahmy, MBBCh, Pediatric Resident (01202626579, Merna.17289584@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean anthropometric z-scores (WAZ, LAZ, WLZ) (time frame: Single assessment at enrollment.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07174999, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in